Zimbabwe has turned down a significant US health deal valued at 367 million US dollars (272 million pounds) spanning five years because of Washington's insistence on sensitive information.
The decision became public following a official document dated December was leaked, indicating that President Emmerson Mnangagwa believed the agreement was "unbalanced".
An official spokesperson has since stated that the US was seeking genetic material for research and profit but refused to guarantee the benefits from any future vaccines.
"We are forced to start the challenging and unfortunate process of scaling back our health aid in Zimbabwe," remarked US ambassador to Zimbabwe Pamela Tremont in a statement.
Her embassy indicated the United States had furnished more than $1.9bn for health programmes to Zimbabwe during the past two decades.
A medical body in Zimbabwe has urged more negotiations to reach a agreement agreeable to all parties so the nation's vital HIV programme can be sustained.
Broader Background
This rejection comes after a similar situation in Kenya, where a court halted a related health funding agreement after concerns were raised about the security of Kenyans' health data.
Since resuming office recently, US President Donald Trump has reduced overseas assistance and shut down the key foreign aid agency.
USAID had administered assistance for the American government, but Trump argued its expenditure was "inefficient" and his administration was pursuing government-to-government deals to boost transparency and responsibility.
According to statements, 16 nations in Africa have to date agreed to similar agreements, representing more than $18.3bn in committed funds.
Specifics of the Rejected Deal
The funds for Zimbabwe was intended to supported "combating HIV/Aids, TB, malaria, maternal and child health, and disease outbreak preparedness.
"We believe this partnership could have provided significant advantages for the people of Zimbabwe, particularly the 1.2 million men, women and children presently on HIV treatment via American-funded programmes," Tremont said.
However, official spokesman Nick Mangwana said the arrangement was "asymmetrical".
"Zimbabwe was being asked to provide its genetic material and health information indefinitely, without any corresponding promise of benefiting from any medical innovations – such as new medicines or tests – that could result from that provided information," he stated.
"Effectively, our nation would supply the basic resources for medical research with no certainty that the final treatments would be accessible to our citizens if a future health crisis arise."
Sovereignty and Global Health
He also said that the American exit from the World Health Organization (WHO) and its push of one-on-one deals were disrupting structures previously established via the international organization.
The spokesperson gave as an example its Pathogen Access and Benefit Sharing framework created to manage future pandemics.
"This mechanism is intended to ensure that when a country contributes its information, the resulting advantages – including medicines and cures – are distributed fairly, not commercialised solely by those with the resources to develop them."
The government's concerns over the US deal "are not meant as opposition to America," he added.
"We are open to ongoing dialogue with our US partners on how subsequent collaboration might be arranged in a way that honours the sovereignty and interests of both nations."
Medical Community Reaction
A leading public health body stated it understood the government's concerns, but urged that negotiations need to persist considering much of the nation's HIV programmes depended on external financing.
"Where specific concerns arise, such as those involving information security or agreement terms, these can often be addressed via technical clarification and mutually agreed protections," it said.
The halted deal underscores the complex challenges between accepting much-needed international aid and protecting national sovereignty in an ever more interconnected world.